Clinical data | |
---|---|
Trade names | Hytrin, Zayasel, others |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a693046 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 90–94% |
Elimination half-life | 12 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.118.191 |
Chemical and physical data | |
Formula | C19H25N5O4 |
Molar mass | 387.440 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. [1] For high blood pressure, it is a less preferred option. [1] It is taken by mouth. [1]
Common side effects include dizziness, headache, tiredness, swelling, nausea, and low blood pressure with standing. [1] Severe side effects may include priapism and low blood pressure. [1] Prostate cancer should be ruled out before starting treatment. [1] It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder. [1]
Terazosin was patented in 1975 and came into medical use in 1985. [2] It is available as a generic medication. [3] In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [4] [5]
Reaction of piperazine with 2-furoyl chloride followed by catalytic hydrogenation of the furan ring leads to 2. This, when heated in the presence of 2-chloro-6,7-dimethoxyquinazolin-4-amine (1) undergoes direct alkylation to terazosin (3).
A 2022 study suggests that terazosin may have the potential to confer neuroprotection upon motor neurons in motor neuron disease, as a result of its ability to activate PGK1. [7]
Clinical data | |
---|---|
Trade names | Hytrin, Zayasel, others |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a693046 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 90–94% |
Elimination half-life | 12 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.118.191 |
Chemical and physical data | |
Formula | C19H25N5O4 |
Molar mass | 387.440 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. [1] For high blood pressure, it is a less preferred option. [1] It is taken by mouth. [1]
Common side effects include dizziness, headache, tiredness, swelling, nausea, and low blood pressure with standing. [1] Severe side effects may include priapism and low blood pressure. [1] Prostate cancer should be ruled out before starting treatment. [1] It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder. [1]
Terazosin was patented in 1975 and came into medical use in 1985. [2] It is available as a generic medication. [3] In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [4] [5]
Reaction of piperazine with 2-furoyl chloride followed by catalytic hydrogenation of the furan ring leads to 2. This, when heated in the presence of 2-chloro-6,7-dimethoxyquinazolin-4-amine (1) undergoes direct alkylation to terazosin (3).
A 2022 study suggests that terazosin may have the potential to confer neuroprotection upon motor neurons in motor neuron disease, as a result of its ability to activate PGK1. [7]